UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 14, 2017

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-37487	13-3632859
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

9635 Granite Ridge Drive, Suite 100 San Diego, California (Address of principal executive offices)	92123 (Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by the registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, the registrant's management as well as estimates and assumptions made by the registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to the registrant or the registrant's management identify forward-looking statements. Such statements reflect the current view of the registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the registrant's industry, the registrant's operations and results of operations and any businesses that may be acquired by the registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although the registrant believes that the expectations reflected in the forward-looking statements are reasonable, the registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, the registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 7.01 REGULATION FD DISCLOSURE.

On March 14, 2017, Mr. James Joyce, Chief Executive Officer of Aethlon Medical, Inc. (the "Company"), presented at the 29th Annual Roth Conference. A link to the presentation may be accessed on the Company's website under the investor relations section of the website. The website address is www.aethlonmedical.com. No portion of the website shall be deemed to be incorporated into this Current Report on Form 8-K.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(d) EXHIBITS

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – 29th Annual Roth Conference – March 14, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: March 14, 2017

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Presentation materials – 29th Annual Roth Conference – March 14, 2017

Aethlon Medical, Inc.

Nasdaq: AEMD

ROTH INVESTOR CONFERENCE

MARCH 14, 2017

Jim Joyce
Chairman, CEO

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com


THERAPEUTIC TECHNOLOGIES TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE
aethlon
MEDICAL, INC.


SAVE LIVES
aethlon
MEDICAL, INC.

CORPORATE FOCUS

- The Treatment of Infectious Viral Pathogens
- Candidate Pipeline
  - Cancer
  - Neurological Disorders
- Exosome Sciences Subsidiary
  - Focused on the discovery of companion biomarkers that underlie Aethlon therapeutic targets

The Aethlon Hemopurifier®

A First-In-Class Broad-Spectrum Technology
Designed For The Single-Use Removal of Viruses From Blood

aethlon MEDICAL, INC.

DEPLOYED WITHIN THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT MACHINES

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

- ✓ Immediate virus elimination
- ✓ Prior to cell & organ infection
- ✓ Inhibits progeny virus replication
- ✓ Companion assay quantifies virus capture
- ✓ Broad-spectrum mechanism

aethlon MEDICAL, INC.

Clinical Development History

- Initiated & Completed
  - ✓ >20 *in vitro* validation studies
  - ✓ Four investigational human studies (outside U.S.)
  - ✓ ~150 human treatment experiences
    - ◆ Hepatitis C virus (HCV), HIV and Ebola virus (EBV)
  - ✓ FDA feasibility study on March 13, 2017

About the Feasibility Study

- A Clinical Safety Study in End-Stage Renal Disease (ESRD) Subjects Infected with Hepatitis C Virus (HCV)
- DaVita Med Center Dialysis – Houston, TX.
- Primary Objective
  - ✓ To demonstrate the safety of the Aethlon Hemopurifier®
  - ✓ No device-related adverse events reported
- Secondary Objective
  - – To quantify the number of viruses captured during treatment
  - – To measure changes in viral load before and after treatment
    - Data being assembled for final FDA report
- Estimated Study Enrollment: 10 Subjects
  - – Concluded at 8 subjects

Forthcoming FDA Submissions

- Submit Feasibility Study Final Report
- File Pre-Submission Document To Request Follow-on Guidance Underlying
  - Market clearance pathways for virulent viruses that do not permit for controlled human studies
  - Study design for viral targets for which controlled human studies are feasible
  - **The 21st Century Cures Act** (became law in December)
    - Mandates a priority review program for medical devices that target diseases for which no FDA-approved alternatives are available

The Global Health Threat of Viral Pathogens
A Significant Therapeutic Void

- 300+ viruses known to be infectious to man
  - Only a fraction are addressed with an antiviral drug
- Only 1 of 13 Category "A" viruses are addressed
  - Easily transmitted, high fatality rate threats likely to disrupt the normal functioning of society
- No solution for antiviral drug resistance
- No solution for the natural emergence of new viruses
- No solution for genetically engineered viruses of mass destruction

"A genetically engineered virus could kill more people than nuclear weapons — and yet no country on Earth is ready for the threat."

Bill Gates
Munich Security Conference
February 18, 2017

Strategic Goal

To fulfill the broad-spectrum medical countermeasure objective of the U.S. Department of Health and Human Services (HHS) 2016 Public Health Emergency Medical Countermeasure Enterprise (PHEMCE). This initiative is directed toward bioterror, pandemic threats and other pathogens that are not well addressed with drug or vaccine therapies.

The Aethlon Hemopurifier®

"The only strategy to address the breadth of viruses that could emerge naturally through mother nature or be created by man as agents of bioterror"

Ken Alibek
Keynote Speech at Crossing Boundaries
International Symposium on Bioterrorism

Former Director of the Soviet Union's
Biological Weapon Program

Author of BIOHAZARD

The Aethlon Hemopurifier®

Opportunities in Viral Indications with an Approved Antiviral Drug

- ✓ Adjunct to improve benefit of antiviral drug agents
- ✓ Antiviral drug resistance



aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Opportunities in Viruses not Addressed with an Antiviral Drug

- ✓ Known pandemic viral threats
- ✓ Naturally emerging viruses
- ✓ Agents of Bioterrorism
  - ◆ Including genetically engineered viruses



aethlon MEDICAL, INC.


In vitro capture study validations
aethlon
MEDICAL, INC.

Chronic Viral Threats

- Hemopurifier Capture Validations
  - ✓ Human Immunodeficiency Virus (HIV)
  - ✓ Hepatitis C Virus (HCV)
- Approved Antiviral Drug (U.S.)
  - – HIV antivirals suppress disease progression
  - – HCV antivirals are often curative
  - ❑ Drug resistance remains a significant issue

Reactivated Latent Viral Threats

- Hemopurifier Capture Validations
  - ✓ Cytomegalovirus (CMV)
  - ✓ Epstein-Barr Virus (EBV)
  - ✓ Herpes Simplex Virus-1 (HSV-1)
- Approved Antiviral Drug (U.S.)
  - CMV (Yes), EBV (No), HSV (Yes)
    - ❑ Significant need for broad-spectrum solution to address immune-suppression related virus reactivation
      - ❑ Opportunity in Sepsis, Organ Transplants

Bioterror/Pandemic Threats

- Hemopurifier Capture Validations
  - ✓ Ebola Virus
  - ✓ Lassa Virus
  - ✓ Middle-East Respiratory Syndrome (MERS-CoV)
  - ✓ Smallpox (Based on Monkeypox & Vaccinia Models)
- Approved Antiviral Drug (U.S.)
  - None
  - Smallpox vaccine in the U.S. National Stockpile

Pandemic Influenza Threats

- Hemopurifier Capture Validations
  - ✓ H1N1 Swine Flu Virus
  - ✓ H5N1 Bird Flu Virus
  - ✓ Spanish Flu of 1918 Virus (reconstructed)
- Approved Antiviral Drug (U.S.)
  - – None for highly virulent influenza strains

Mosquito-Born Pandemic Threats

- Hemopurifier Capture Validations
  - ✓ Chikungunya Virus
  - ✓ Dengue Virus
  - ✓ West Nile Virus
  - ✓ Zika Virus
- Approved Antiviral Drug (U.S.)
  - – None


Proof of Concept Against a Highly Virulent Virus
aethlon
MEDICAL, INC.

The Treatment of Ebola Virus

Frankfurt University Hospital

Special approval from The Federal Institute for Drugs and Medical Devices (BfArM)

aethlon MEDICAL, INC.

Hemopurifier® therapy administration to a comatose Ebola patient with multiple-organ failure

aethlon MEDICAL, INC.

Dr. Stefan Büttner
Holding Hemopurifier®
After Ebola Treatment

aethlon MEDICAL, INC.

Ebola Treatment Data

Presented By Dr. Helmut Geiger
American Society of Nephrology Annual Meeting

- 6.5 hour Hemopurifier® therapy administration
- Pre-treatment viral load: 400,000 copies/ml
- Post-treatment viral load: 1,000 copies/ml
- Patient made full recovery
- Companion assay validated capture of 258M viruses
  - Hemopurifier® since approved in United States & Canada under Emergency-Use provisions


TIME
"Top 25 Best Inventions"
"11 Most Remarkable Advances in Healthcare"
aethlon
MEDICAL, INC.

The Aethlon Hemopurifier®

A Potential Role in Other Disease Conditions

aethlon MEDICAL, INC.

Candidate Pipeline
Targeting Disease Promoting Exosomes

- Cancer
  - Tumor-derived exosomes promote spread of metastasis and immune suppression
  - ✓ Capture of Breast, Ovarian and Melanoma Validated
- Tauopathies
  - A class of 20+ neurodegenerative disorders
  - Hallmark is abnormal aggregation of tau protein in brain
  - Exosomes discovered to be a tau transport mechanism
  - Exploratory phase
    - Alzheimer's Disease, Chronic Traumatic Encephalopathy (CTE)


Exosome
Sciences
aethlon
MEDICAL, INC.

Discovery of TauSome™
A Candidate Tauopathy Biomarker

Exosome Sciences

aethlon MEDICAL, INC.


A BIOMARKER TO DIAGNOSE CHRONIC TRAUMATIC ENCEPHALOPATHY (CTE) IN THE LIVING?
aethlon
MEDICAL, INC.


Exosome
Sciences
• TauSome testing was conducted in the DETECT study
– In collaboration with the Boston University CTE Center
– First NIH funded CTE research study
– 78 former NFL players (high risk CTE group)
– 16 athlete controls (low risk CTE group)
aethlon
MEDICAL, INC.

Preliminary Study of Plasma Exosomal Tau as a Potential Biomarker for Chronic Traumatic Encephalopathy

Stern, Tripodis, Baugh, Fritts, Martin, Chaisson, Cantu, Joyce, Shah, Ikezu, Zhang, Gercel-Taylor, & Taylor

J Alzheimer's Disease, 2016

- Findings suggest that TauSome plasma levels may be an accurate, noninvasive CTE biomarker
  - TauSome levels significantly higher in the NFL group
  - TauSome levels correlated with cognitive decline


Control Samples
- n=16
- Avg: 310,000,000 TauSomes/mL
- SD: 1.9 E8
NFL Player Samples
- n=78
- Avg: 2,800,000,000 TauSomes/mL
- SD: 2.9 E9
TauSome Concentration (x10⁹/mL)
0
2
4
6
8
10
12
14
16
18
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51 53 55 57 59 61 63 65 67 69 71 73 75 77 79 81 83 85 87 89 91 93
Patient Samples
aethlon MEDICAL, INC.
*Horizontal lines represent average TauSome concentration for each group.


WE ALSO HAD THE OPPORTUNITY TO EXPLORE
TAUSOME™ LEVELS IN ALZHEIMERS'S PATIENTS
aethlon
MEDICAL, INC.


Previously Unreleased Data
TauSome Concentration (x10⁹/mL)
18
16
14
12
10
8
6
4
2
0
Control Samples
- Avg: 0.31
- SD: 0.19
NFL Samples
- Avg: 2.8
- SD: 2.9
AD Samples
- Avg: 3.1
- SD: 1.8
16 Control Samples
78 NFL Player Samples
33 Alzheimer's Patient Samples
*Horizontal lines represent average TauSome concentration for each group
aethlon MEDICAL, INC.


Exosome Sciences
• Next Steps
– Continued AD and CTE Validations
– Follow-on TauSome study in former NFL players to kick-off in Q2
aethlon MEDICAL, INC.


THERAPEUTIC TECHNOLOGIES TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH & BIODEFENSE
aethlon
MEDICAL, INC.

The Aethlon Hemopurifier®

A First-In-Class Broad-Spectrum Technology
Designed For The Single-Use Removal of Viruses From Blood

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

A Broad-Spectrum Strategy To Address

- ✓ Drug Resistant Viruses
- ✓ Emerging Pandemic Threats
- ✓ Bioterror Threats
- ✓ Genetically Engineered Viruses

aethlon MEDICAL, INC.


SAVE LIVES
aethlon
MEDICAL, INC.

Acknowledgement and Thanks

- Team Aethlon
- Battelle Memorial Research Institute
- Boston University CTE Center
- DaVita Med Center Dialysis
- Defense Advanced Research Projects Agency (DARPA)
- Frankfurt University Hospital
- Medanta Medicity, Fortis and Apollo Hospitals
- National Institute of Virology (NIV) Pune, India
- Philipps University Marburg
- U.S. Army Medical Research Institute for Infectious Diseases (USAMRIID)
- U.S. Centers for Disease Control (CDC)

CONTACT:

Aethlon Medical, Inc
9635 Granite Ridge Drive
Suite 100
San Diego, California 92123

Jim Joyce
Chairman & CEO
jj@aethlonmedical.com
858.459.7800 x301